Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (171)	1/4/2002 11:19:43 AM
From: Michael Young	Respond to of 897

It is a SEPR type play. They allow big pharma to extend the patent lives of drugs with new release or dosing technology. They have a generic element, but that is rapidly shrinking. I like it as a more "conservative" play as they are expected to grow earnings in excess of 30% for a number of years. MIKE

To: tuck who wrote (171)	1/22/2002 4:58:59 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 897

Disease Science still making news. In September it was Prions. I guess they were discouraged with the failure to achieve a BSE breakthrough in 120 days. Disease Sciences to Begin Marketing New Line of Super Antioxidants BOCA RATON, Fla.--(BUSINESS WIRE)--Jan. 22, 2002--Disease Sciences, Inc. (OTC BB: DSSC - news) announced today that it will soon commence the marketing and sale of a proprietary line of compounds. These proprietary compounds or Super Antioxidants that are many times more potent and effective than conventional antioxidants, such as Vitamin C and E in lowering the production of free radicals and reducing oxidative stress. The proprietary compounds also include formulated omega-3 oils that do not cause the digestive side effects that are typical of standard fish-oil supplements. Targeted applications of these supplements will include but not be limited to, slowing of age related diseases. Many studies show that antioxidants and omega-3 oils promote cardiovascular health and reduce the risk of degenerative age-related diseases. Disease Sciences plans on building distribution channels through joint marketing agreements, e-commerce and conventional retail sales. Dr. Bryant Villeponteau, CSO stated, ``based on our animal data and human clinical testing, we believe HealthSpan's patent pending and trademarked super antioxidants are the most powerful available today.'' ``We are very excited about the prospect of a revenue stream this early in our development. A source of revenues will allow us to continue our rapid expansion through further mergers and acquisitions, joint research and drug development activities,'' stated Dr. Wayne Goldstein, CEO.